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Dear Editor,
The increasing worldwide incidence of inflammatory bowel diseases (IBD) steadily parallels the diffusion of Western life style [1] . Diet is considered the main factor associated with life style and induces significant alteration in the gut microbiome, the "ring chain" that can explain new onset of diseases, particularly inflammatory diseases [2] [3] [4] .
Obesity also poses a major risk, not only for diet-related non-communicable diseases, such as diabetes, but also for IBD [5] . Currently, bariatric surgery is the more appropriate therapeutic option for obese patients who failed an adequate exercise and diet program, and who present with obesityrelated comorbid conditions. Few data about the efficacy and safety of bariatric surgery in patients affected by IBD are available in literature, probably due to the fear to perform abdominal surgery in these patients [6, 7] .
In a recent interesting paper, McKenna et al. described the outcomes of 31 patients affected by IBD who underwent bariatric surgery, including Roux-en-Y gastric bypass (RYGB), sleeve gastrectomy (SG), and gastric band placement, at Mayo Clinic in Rochester, MN [8] . They concluded that, in carefully selected IBD patients (in particular upon exclusion of Crohn's disease patients with upper gastrointestinal active disease location), bariatric surgery seemed to be not only effective (weight lost at 1 and 2 years after surgery was of about 70% and 60%, respectively, comparable with the literature data [9] ), but also safe (they did not observe any major surgical complication and no IBD patients relapsed).
These results raise two issues. This study [8] supports the feasibility of bariatric surgery in patients with IBD, but a comparison with a control group of patients without IBD, matched for sex, age, and comorbidities, who underwent bariatric surgery, would add more objective data regarding safety and efficacy of this type of intervention. Furthermore, a comparison of two IBD groups, one that underwent bariatric surgery and a control non-surgical group, would provide further information concerning the IBD evolution related to surgery.
The second issue is a suggestion regarding the design of future studies on bariatric surgery in IBD patients. As reported above, microbiota, obesity, and inflammation are believed to share a strong relationship. In our opinion, future studies should analyze gut microbiome of IBD patients before and after bariatric surgery and correlate differences with IBD course after this intervention. The question that remains is: could bariatric surgery, with its extraordinary effects on weight loss, be not only safe but also effective in reducing inflammation, through modification of gut microbiome?
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